Page 84 - Aet News Today

Digital therapeutics will be one of the topics discussed at INVEST Digital Health scheduled for October 26 at Health Wildcatters headquarters in Pegasus Park in Dallas. Register today!

Intercept Pharmaceuticals’ acquisition by Alfasigma comes three months after the FDA again rejected the biotech’s drug as a treatment for the fatty liver disease NASH. But Intercept still has rare liver disease assets, and Italy-based Alfasigma says acquiring the company will help it expand in gastroenterology and hepatology.

As value-based care models take hold, the time is ripe for rehab therapists to position themselves as primary players in the movement toward delivering optimal quality and value in the broader healthcare ecosystem.

Scynexis said no adverse events or contamination problems have been reported for Brexafemme, an antifungal approved for treating vaginal yeast infections. The biotech said the risk of cross-contamination stems from the processes of the small molecule’s third-party manufacturer.

Although employee stress and burnout are critical issues in all industries, the healthcare industry offers numerous examples of the impact on staff as well as ways to provide short and long-term solutions. These topics will be part of the discussion at the HLTH event October 8-11 in Las Vegas. Register today to join the conversation!

Issues around healthcare affordability, mental health challenges and worsening chronic conditions are all top of mind for Ellen Kelsay, president and CEO of Business Group on Health.

There are concerns that Medicare Advantage TV ads are misleading patients. A new KFF analysis of Medicare Advantage TV ads found that the ads often rely on celebrity endorsements and suggest that seniors are missing out on benefits that they're entitled to.

Zocdoc launched a new suite of tools to compete with the solutions sold by Phreesia, NexHealth and Solutionreach. The product suite, which is free for any provider to use, includes tools to streamline the patient intake process, facilitate online scheduling and enable video visits.

Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that’s more scalable and less expensive than current methods. The startup is raising a Series A round of financing to further demonstrate the potential of its technology.

The next generation of senior living searchers are markedly different from their predecessors, and they will challenge us to work together to reshape their search experience.